Grants and Contracts Details
Description
HUMAN CLINICAL TRIAL - CONFIDENTIAL
The study design is a randomized effectiveness study to evaluate
the effectiveness of DOAC therapy compared to usual care with
LMWH/warfarin. Participants who decline randomization will be
offered the opportunity to participate in the preference cohort.
This is a hybrid design that consists of both a randomized cohort
and a preference cohort. Eligible patients who accept
randomization will be enrolled in the study (the randomized
cohort), and they will be randomly assigned to either the DOAC
therapy group (Arm 1) or the usual care group (Arm 2). Those
patients who decline randomization but choose treatment on one
of the two study arms (Arm 1 or Arm 2) will be enrolled to the
study (the preference cohort).
Status | Finished |
---|---|
Effective start/end date | 4/25/17 → 10/10/22 |
Funding
- Alliance Foundation Trials LLC: $23,250.00
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.